Close Menu

New Products

Feb 19, 2019

Clear Labs Clear Safety NGS Platform

Clear Labs has released a software update for its Clear Safety NGS platform, which now includes Salmonella serotyping. According to the firm, food safety professionals can now detect up to 40 unique Salmonella serotypes in an enriched sample in about 24 hours. With the update, Clear Labs said that the platform allows food manufacturers and service labs to test for the presence or absence of pathogens and serotypes at the same time. In addition, the firm noted that customers can now choose if they want to test for the disease at the genus level, species level, or the serotype level. 

Feb 12, 2019

Arrow Diagnostics ArrowforNGS Microbiota Solution A/B

Arrow Diagnostics has launched two library preparation kits for bacterial 16S rRNA gene sequencing, called ArrowforNGS Microbiota Solution A/B. The kits come with dedicated analysis software. Microbiota Solution A amplifies 16S hypervariable regions V1-V2-V3 and Microbiota Solution B amplifies 16S hypervariable regions V3-V4-V6. Both kits are compatible with the Illumina MiSeq sequencing platform.

Feb 12, 2019

Varigen Biosciences Biosynthetic Gene Cluster Custom Cloning Service

Varigen Biosciences has launched custom cloning of bacterial or fungal biosynthetic gene clusters of up to 100 kb in length. The company said that its DNAtrap technology enables it to deliver intact gene cluster clones from microbes in 10 days. Varigen has cloned 32 PKS, NRPS, and other pathways of interest with high fidelity from dozens of bacterial and fungal strains. In addition, for already-cloned pathways the firm offers shuttling to its new heterologous BGC expression vector.

Feb 12, 2019

Bode Technology Forensic Genealogy Service

Bode Technology has launched a new forensic genealogy service to law enforcement investigators and crime laboratories. The service provides forensic accredited DNA services for sample handling, extraction, and confirmation testing. The tool integrates advanced DNA testing and genealogy to develop ancestral relationships between the samples and deliver leads to the firm's clients. By using its forensic laboratory, clinical testing laboratory, and experienced genealogists, Bode said it has developed a high-quality, turn-key solution for clients from sample submission through confirmation testing. 

Feb 12, 2019

Promega Maxwell RSC miRNA Plasma, Serum Kit

Promega has launched its Maxwell RSC miRNA Plasma and Serum kit. The firm said that the kit offers oncology and translational researchers a simple and automated protocol to purify circulating RNA — including miRNA — from plasma, serum, and enriched exosomes for techniques such as next-generation sequencing or droplet digital PCR. Researchers can use the kit with Promega's Maxwell RSC and RSC 48 instruments, which the firm said will reduce hands-on time for researchers and provide consistent, high-quality, and amplifiable miRNA. 

Feb 12, 2019

Myriad Genetics Prequel

Myriad Genetics commercially launched an enhanced version of the Prequel Prenatal Screen. The enhanced noninvasive prenatal screen analyzes 23 chromosome pairs instead of the standard five chromosomes (13, 18, 21, X and Y) it previously gauged. According to the company, the ability to assess additional chromosomes enhances the test's clinical utility by improving aneuploidy detection by 30 percent. Myriad is combining the NIPS Prequel tests with its Foresight Carrier Screen and is marketing them to all female patients, including women who have a high body mass index, are an ovum donor, or have a twin pregnancy. The expanded offering will be available for doctors to order on Feb. 19. 

Feb 12, 2019

Invitae NIPS

Invitae has added non-invasive prenatal screening (NIPS) to its offerings and integrated it as part of the firm's carrier screening test. The NIPS test analyzes cell-free DNA to assess whether a pregnancy is at heightened risk for three common chromosomal disorders, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome). There is no additional charge for adding microdeletion and sex chromosome analysis. The carrier screen sequences 301 genes linked to serious genetic disorders, and now the same specimen collection kit will also enable NIPS. Invitae will begin accepting NIPS test orders next week.

Feb 08, 2019

MGI Automated Sample Prep Workstations

MGI, a subsidiary of BGI, has introduced its MGISP series of automated sample preparation workstations worldwide. The portfolio includes the MGISP-960, a workstation with options for built-in thermocycler for PCR, isotherm stage, shaker, magnetic racks, and on-deck functions that prepare up to 96 samples simultaneously. According to the firm, the tool covers several applications, including genomics, cell biology, drug discovery, and protein science. In addition, MGI has introduced the MGISP-100, a 16 sample automated workstation that it said is optimized for NGS applications. 

Feb 07, 2019

ArcticZymes T4 DNA Ligase

ArcticZymes, a Biotec Pharmacon subsidiary, has released a T4 DNA ligase, its first commercial ligase enzyme. T4 DNA ligase is the most widely used enzyme in the ligase family, and works by joining DNA fragments together. It is used in the development of kits and products for in vitro diagnostics and molecular research. The ligase is produced under strict ISO 13485 guidelines, and can be used by customers either in combination with their own enzymes or alongside other ArcticZymes enzymes.

Feb 06, 2019

Illumina NovaSeq 6000 S Prime Reagent Kits

Illumina has launched its S Prime Reagent Kits for the NovaSeq 6000 next-generation sequencing instrument. The kits, which are available in 100-, 300-, and 500-Cycle configurations, enable paired-end reads as long as 250 bases. They require run times of 13 hours for 50-base paired end reads and up to 38 hours for 250-base paired end reads. Illumina said that total throughput is between 65 and 400 gigabases, depending on the read length.

Feb 06, 2019

OncoDNA NTRK Gene Fusion Assay

OncoDNA has released its OncoNTRK assay for solid or liquid biopsies analysis of tumors with potential NTRK gene fusions. According to the firm, the assay is the first commercial kit available for NTRK 1, 2, and 3 gene fusion profiling based on RNA-sequencing. OncoDNA said that the assay is particulary interesting for use in non-small cell lung cancer, pediatric glioblastoma, and thyroid cancer.

Feb 05, 2019

Baylor Genetics Clinical Whole-Genome Sequencing for Genetic Disorders

Baylor Genetics has launched clinical whole-genome sequencing for the diagnosis of rare genetic and inherited disorders. The test covers various mutation types throughout the genome, including single-nucleotide variants, indels, copy number variants, structural variants, regions of absence of heterozygosity, and repeat expansion variants. It requires a sample from patient and parents and has a turnaround time of 8 to 10 weeks.

Feb 05, 2019

Caris Life Sciences MI Transcriptome

Caris Life Sciences has launched a whole-transcriptome assay, MI Transcriptome, to sequence the transcriptome of patients' tumors. The assay generates on average 60 million reads per patient to enable detection of fusions, splice variants, and gene expression. The company plans to submit the assay to the US Food and Drug Administration for pre-market approval review in the first half of the year.

Feb 05, 2019

Tecan NGS DreamPrep

Tecan has launched NGS DreamPrep, an automated next-generation sequencing library prep instrument. NGS DreamPrep combines Tecan's Fluent liquid handler, Infinite plate reader, and Celero DNA-Seq and Universal Plus mRNA-Seq library prep kits.

Feb 05, 2019

Saphetor VarSome Pro

Saphetor released VarSome Pro, a paid, enhanced version of the free VarSome genomic annotation software tool aimed at researchers. The Swiss company said that VarSome Pro features advanced variant filtering and annotation of whole VCF files for single and multiple samples, gene panels, exomes, and genomes. Saphetor also recently rebranded its Saphetor Portal next-generation sequencing interpretation platform as VarSome Clinical. 

Feb 04, 2019

Oxford Nanopore Technologies Direct cDNA (SQK-DC109), PCR-cDNA (SQK-PCS109) Kits

Oxford Nanopore Technologies has launched two new cDNA sequencing kits for its nanopore devices. The kits, called Direct cDNA (SQK-DC109) and PCR-cDNA (SQK-PCS109), generate sequence data for full-length cDNA and require less than five hours of sample preparation. The Direct cDNA kit does not require PCR and needs 100 ng of poly-A+ RNA. The PCR-cDNA kit has an input requirement of just 1 ng of polyA+ RNA and can start from total RNA. Users can obtain 10 to 15 million reads on a MinIon flow cell and more than 60 million reads on a PromethIon flow cell. According to the firm, the kits are available for the MinIon, GridIon, and PromethIon sequencers.

Feb 04, 2019

Viracor Eurofins Baloxavir marboxil (Xofluza) Influenza A Antiviral Resistance PCR

Viracor Eurofins has launched its test for resistance to the antiviral Xofluza (baloxavir marboxil). The Baloxavir marboxil (Xofluza) Influenza A Antiviral Resistance PCR detects I38T/M/F mutations in H3N2 and 2009 H1N1 strains of influenza A and aids in evaluating resistance to the drug developed by Shionogi and Roche. Results can be available to healthcare providers within eight to 12 hours from the receipt of nasopharyngeal swab at Viracor's lab, the company said. 

Feb 04, 2019

Ncardia DiscoverHit Drug Screening Platform

Ncardia has launched the DiscoverHit drug screening platform, a service intended to help researchers access disease-relevant biology earlier in the drug-discovery process. DiscoverHit is a phenotypic drug screening platform comprising genetic and induced human pluripotent stem cell-derived cardiac and neural disease models; controlled bioreactor-based manufacturing to enable batch sizes compatible with high-throughput screening; customized development of disease-relevant assays; and high-throughput screening combined with high-content data acquisition and analysis.

Feb 04, 2019

Fluidigm REAP-Seq Protocol for C1 System

Fluidigm has introduced a REAP-seq (RNA expression and protein sequencing) protocol for use with its C1 sample prep system for single-cell genomics. C1 REAP-seq enables characterization of unique cellular subtypes and functional states by measuring the expression of both cellular proteins and RNAs. Users can pair the protocol with functional imaging assays that measure differences in cell size, morphology, or phenotype within the clear C1 microfluidic cell chambers. The firm developed C1 REAP-seq in collaboration with Merck for co-detection of both cellular protein and RNA using microfluidic technology.

Feb 04, 2019

Genoox AI, Data Aggregation

Genoox has updated its technology platform to include artificial intelligence to process new clinical evidence in an effort to "promote regular and periodic genomic data reanalysis and data aggregation to quicken diagnoses for patients," the company said in a statement. The update is intended to help clinicians improve diagnostic yield.

Jan 28, 2019

Biocept Target Selector Kits

Biocept has announced the availability of the first research-use-only (RUO) assay in a planned menu of kits for labs to run its Target Selector circulating tumor DNA assays in house.  The first assay being released is for high-sensitivity detection of EGFR mutations, which are among the most frequently evaluated biomarkers for lung cancer. Additional RUO test kits for other oncogene mutations are planned for launch in the future.

All will use Biocept's proprietary "switch blocker" technology, which the firm says produce industry-leading sensitivity for the detection of variants of interest. The EGFR kit and other assays can be used on a variety of analytical platforms including qPCR, Sanger sequencing, microarrays, mass-spectrometry, and next generation sequencing. 

Jan 24, 2019

Oxford Nanopore PromethIon 24, PromethIon 48

Oxford Nanopore Technologies said this week that its PromethIon 24 and PromethIon 48 sequencing platforms are now available for users to order. The instruments can run up to either 24 or 48 flow cells, respectively, and include a computer for real-time data analysis. The run time ranges from 1 minutes to 64 hours, and the best yield per run with 1D reads so far has been 7.6 terabytes, based on customer data, with a theoretical maximum of 15 Tb. There is no instrument cost, but users must pay for a $20,000 annual service contract. Flow cells range in price from $625 to $2,000, depending on order type and volume, and reagent costs per run are $99.

Jan 22, 2019

Intermountain Healthcare Precision Genomics ICG100 Myeloid Malignancies Panel

Intermountain Healthcare Precision Genomics has announced its ICG100 Myeloid Malignancies Panel to help classify and diagnose multiple blood cancer types. The panel includes 63 genes and uses peripheral blood, bone marrow aspirate, extracted DNA, or fixed samples to detect faulty gene alterations through next-generation sequencing. According to the firm, the panel identifies variants in genes linked to several cancers, including acute myeloid leukemia, myeloid proliferative neoplasm, myeloid dysplastic syndrome, and myeloid dysplastic/myeloid proliferative overlap disorders. 

Jan 22, 2019

AusDiagnostics Dermatophytes IVD Kit

AusDiagnostics has released a new in vitro diagnostic kit that detects dermatophytes and other fungi. According to the firm, the new kit will produce a result in four hours, allowing medical professionals to advise their patients on the best course of treatment. AusDiagnostics said that the kit detects species of Microsporum, Trichophyton, and Epidermophyton, as well as identifying six common dermatophytes and six Candida species. 

Jan 22, 2019

Horizon Discovery CRISPR Screening Service for Primary Human T Cells

Horizon Discovery has extended its CRISPR Screening Service to include ex vivo T lymphocytes. Horizon has adapted its established CRISPRko (knockout) platform to screen human T lymphocytes, adding CRISPRko screens in ex vivo T lymphocytes to its established CRISPR screening formats – CRISPRko, CRISPRi (interference) and CRISPRa (activation) – in cancer cell lines. The service extension meets the requirements of immunology-based research in drug discovery, allowing for the identification of new gene targets in biologically and potentially therapeutically relevant settings, the firm said.

Pages

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.